Through 2027, the Eastern European market for IC devices will expand modestly, with the expanding CAD population supporting an increase in procedure volumes. However, overall revenue growth will be strongly limited by economic constraints that will drive pricing pressure and hinder adoption of premium-priced technologies such as next-gen DES, BVS, DCBs and imaging devices.
This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for interventional cardiology in Eastern Europe across a 10-year period.
Most segments of the Eastern Europe IC device market are dominated by large international manufacturers.
Which companies are the leading competitors in each of the IC device segments?
What competitive strategies can firms use to maintain and/or improve their competitive positions going forward?
Penetration of DCBs is rising Eastern Europe; however, adoption of BVS will be hindered by recent clinical trial results.
To what extent will both these devices be adopted amid cost-containment efforts?
How will adoption of both these devices affect ASPs and market growth?
What impact will recent events in the BVS space have on DES usage patterns?
The use of intravascular imaging catheters and pressure guidewires will expand rapidly in Eastern Europe.
How will adoption of these devices affect other IC device markets?
Which countries will be more aggressive in adopting these devices?
What strategies are competitors implementing to capture share in this growing market?
- Interventional Cardiology Devices - Market Insights - Eastern Europe
Author(s): Sangeetha Iyer, Pharm.D
Sangeetha Iyer is an analyst within the Cardiovascular Medtech Insights team at Decision Resource Group, specializing in structural heart closure and vascular access device markerts across the Asia Pacific region, as well as medical device pricing and regulations in China and Japan. Sangeetha has represnted India at the European Society of Cardiology confrerence in Greece(2016) and Sweden(2017), where her research poster was awarded the top prize. Sangeetha holds a Doctor of Pharmacy degree from the Manipal Academy of Higher Education. Follow Sangeetha on twitter: @Slyer_DRG